Tag: cytokinetics
August 27, 2019
Cytokinetics and Cure SMA Renew Partnership
Cure SMA and Cytokinetics (NASDAQ:CYTK) have renewed their partnership to increase and raise awareness for spinal muscular atrophy (SMA). As... July 23, 2019
Cytokinetics Granted European Orphan Designation for Reldesemtiv to Treat Spinal Musclar Atrophy
Cytokinetics (NASDAQ:CYTK) has announced that the European Medicines Agency (EMA) has granted the company orphan medicinal product designation to reldesemtiv... February 20, 2019
Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator
Cytokinetics (NASDAQ:CYTK) has announced the first subject has been dosed in a Phase 1 randomized, double-blind, placebo-controlled and multiple ascending... December 5, 2018
Cytokinetics Announces Initiation of Phase 1 Clinical Trial of CK-3773274
Cytokinetics (Nasdaq:CYTK) announced the first subject has been dosed in a Phase 1 double-blind, randomized, placebo-controlled, multi-part, single and multiple... October 5, 2018
Cytokinetics and Astellas Provide Updates Regarding Collaborative Skeletal Muscle Program
Cytokinetics (Nasdaq:CYTK) and Astellas Pharma (TSE:4503) today provided an update for their collaborative skeletal muscle program, including clinical trial updates... April 27, 2018
Cytokinetics Reports First Quarter 2018 Financial Results
Cytokinetics (Nasdaq:CYTK) reported financial results for the first quarter of 2018. Net loss for the first quarter was $30.3 million,... February 16, 2018